Myla Goldman is a Neurology physician affiliated with Virginia Commonwealth University. OpenAlex indexes 154 publications with 6,175 citations (h-index 38); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Clinical Importance of Glucose Regulation in Relapsing MS
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
4 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
53.4%Potassium Channel Blocker13.3%Dalfampridine Er100%Part D≥15 patientsGabapentinoids10.1%Gabapentin100%Part D≥20 patients+ 9 more classes in this area
Cancer & immunology
26.4%CD20-directed Cytolytic Antibody14.2%Kesimpta Pen100%Part D<11 patientsOther immunosuppressants6.2%Dimethyl Fumarate58%Tecfidera42%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
18%gamma-Aminobutyric Acid-ergic Agonist11.1%Baclofen100%Part D≥25 patientsCentral alpha-2 Adrenergic Agonist6.9%Tizanidine Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2009–2013 per NIH RePORTER. The latest:
- Validation of a Motor Fatigue Measure in Multiple Sclerosis
University of Virginia
FY2013$183,881K23NS062898 - Validation of a Motor Fatigue Measure in Multiple Sclerosis
University of Virginia
FY2012$183,881K23NS062898 - Validation of a Motor Fatigue Measure in Multiple Sclerosis
University of Virginia
FY2011$170,997K23NS062898
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Jasmohan Bajaj, MD
Virginia Commonwealth University
Velimir Luketic, MD
Virginia Commonwealth University
Patrick Ching, MD, MPH
Virginia Commonwealth University
Robert Delorenzo, MD
Virginia Commonwealth University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”